What is the effect of statins on amputations, and survival in peripheral vascular disease?

indicación de tratamiento con estatinasThe prevalence of peripheral arterial disease is between 15% and 20% of patients older than 65 years and its severity is greatly underestimated. In fact, annual mortality is higher in patients with peripheral arterial disease (8.2%) than in those after acute myocardial infarction (6.3%). Despite the above, medical advice and efforts to modify risk factors are far below those observed in those with coronary heart disease or stroke.

Definitely we are doing something wrong…


Read also: Statin Pre-Treatment for the Prevention of Peri-Procedural Events in Carotid Artery Stenting.


The guidelines for the indication of statins in peripheral vascular disease, are largely extrapolated from the data of coronary disease or stroke. Therefore, the objective of this study was to determine the effect of the intensity of statin treatment in this specific population over hard end points such as amputation and mortality.

An intensive treatment with statins was compared with a moderate/mild treatment and antiplatelet therapy, but without statins.

A cohort of 155,647 patients with peripheral vascular disease was included, of which more than a quarter (28%) were not receiving statins.


Read also: When to Indicate Statin Therapy.


The use of intensive treatment was only 6.4%, compared to 18.4% of those with a diagnosis of coronary or carotid disease.

The incidence of amputation and death, decreased significantly with any dose of statins versus antiplatelet therapy alone. But this reduction was also increasing as the intensity of the treatment increased (intensive treatment amputation HR 0.67, CI 95% 0.61 to 0.74 versus mild/moderate treatment; amputation HR 0.81 0.75 to 0.86 and intensive treatment mortality HR 0.74, CI 95% 0.70 to 0.77 versus mild/moderate mortality HR 0.83 0.81 to 0.86 with p<0.001 for all comparisons).


Read also: Early Endarterectomy Seems Superior to Carotid Stenting in Symptomatic Patients.


The association between the intensity of statin treatment and the reduction of amputations and death, remained significant after adjustment with propensity score, sensitivity analysis and subgroup analysis.

Conclusion

Statins, particularly aggressive schemes, are underutilized in peripheral vascular disease. This is the first population study that shows that the intensity of statin treatment at the time of diagnosis of peripheral vascular disease is associated with a reduction in amputations and mortality.

Original title: Statins Have a Dose-Dependent Effect on Amputation and Survival in Peripheral Artery Disease Patients.Reference: Shipra Arya et al. Circulation. 2018 Jan 12. Epub ahead of print.

Reference: Shipra Arya et al. Circulation. 2018 Jan 12. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...